|
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | - | Shs Outstand | - | Perf Week | -6.15% |
| Market Cap | - | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | - | Perf Month | -14.61% |
| Income | - | PEG | - | EPS next Q | - | Inst Own | - | Short Float | - | Perf Quarter | -36.44% |
| Sales | - | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | - | Perf Half Y | -51.88% |
| Book/sh | - | P/B | - | EPS next Y | - | ROA | - | Target Price | - | Perf Year | -66.95% |
| Cash/sh | - | P/C | - | EPS next 5Y | - | ROE | - | 52W Range | 13.16 - 42.06 | Perf YTD | -46.35% |
| Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -67.36% | Beta | - |
| Dividend % | - | Quick Ratio | - | Sales past 5Y | - | Gross Margin | - | 52W Low | 4.33% | ATR | 0.76 |
| Employees | - | Current Ratio | - | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 36.03 | Volatility | 4.25% 5.74% |
| Optionable | Yes | Debt/Eq | - | EPS Q/Q | - | Profit Margin | - | Rel Volume | 1.66 | Prev Close | 13.90 |
| Shortable | Yes | LT Debt/Eq | - | Earnings | - | Payout | - | Avg Volume | 1.38M | Price | 13.73 |
| Recom | - | SMA20 | -3.33% | SMA50 | -20.22% | SMA200 | -43.74% | Volume | 2,292,806 | Change | -1.22% |
 |
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from the marijuana and hemp business in the United States and in derivatives that have economic characteristics similar to such securities. It will concentrate at least 25% of its investments in the pharmaceuticals, biotechnology & life sciences industry group within the health care sector. The fund is non-diversified. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| open in yahoo | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite